A panel of 47 North American experts has developed 82 consensus best practices for delivering neoadjuvant therapy in pancreatic ductal adenocarcinoma, using a modified Delphi process to standardize and optimize care. This effort aims to improve treatment approaches, reduce variability in care, and enhance patient outcomes.
The study outlines best practices across the entire neoadjuvant therapy continuum, including pre-treatment evaluation, therapy initiation, restaging protocols, management of complications, surgical decision-making, pathology assessment, and follow-up. These guidelines establish a comprehensive framework for delivering neoadjuvant therapy in a way that ensures consistency across multiple disciplines, including oncology, radiology, surgery, pathology, and supportive care.
Optimizing the delivery of neoadjuvant therapy is critical to improving prognosis and ensuring the completion of multimodal treatment strategies. Standardizing protocols represents an important step toward reducing disparities in care and enhancing patient outcomes. Future research will focus on validating these standards and integrating them into clinical practice.
